GlassScriptPhysician profile
Todd E Crawford
NPI 1770563892
$2,861.77
in general payments reported to CMS, 2019-2025
20 companies · $761 in 2025
The $761 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $691 · 2022: $91.60 · 2023: $373 · 2024: $945 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,980.16 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $468.59 | 2023-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $427.67 | 2021-2025 | Winrevair, Verquvo |
| Novartis Pharmaceuticals Corporation | $373.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $290.02 | 2021-2025 | Wainua, Farxiga |
| Amgen INC. | $192.63 | 2021-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $139.93 | 2021-2025 | Camzyos |
| Pfizer INC. | $114.58 | 2022-2025 | |
| Abiomed | $110.98 | 2022-2024 | Impella |
| United Therapeutics Corporation | $108.01 | 2021-2025 | Tyvaso, Tyvaso, Remodulin |
| Novo Nordisk INC | $85.12 | 2024-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.21 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $81.63 | 2023-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $73.50 | 2021 | |
| Janssen Pharmaceuticals, INC | $72.49 | 2021 | |
| Alnylam Pharmaceuticals INC. | $64.85 | 2023-2025 | Onpattro |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $60.57 | 2025 | Attruby |
| Abbott Laboratories | $45.00 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Abbvie INC. | $32.08 | 2021 | |
| Scpharmaceuticals INC. | $24.21 | 2024 | |
| Boston Scientific Corporation | $12.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.